Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RETRO: BXQ-350 in CIPN
NCT05291286Phase 1Completed
- Sponsor
- Bexion Pharmaceuticals
- Start
- Oct 2022
- Primary completion
- Dec 2024
- Modality
- Recombinant Proteins and Enzymes, Nanoparticles
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in chemotherapy-induced peripheral neuropathy (CIPN) comparing BXQ-350 with Placebo (2 arms). Primary endpoints: Peak Plasma Concentration at 6 months, Ceramide at 6 months and 5 more. Started Oct 2022; status: completed.
02
Drugs
BXQ-350
03
Conditions
chemotherapy-induced peripheral neuropathy (CIPN)
Beyond the preview
Go deeper on NCT05291286.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05291286.